Advertisement
Editorial| Volume 2, ISSUE 3, P153, July 2013

Download started.

Ok

Editorial

  • Brenda Banwell
    Affiliations
    Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, 5 East 98th Street; Box 1138, New York, NY 10029-6574, United States
    Search for articles by this author
  • Gavin Giovannoni
    Affiliations
    Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, 5 East 98th Street; Box 1138, New York, NY 10029-6574, United States
    Search for articles by this author
  • Christopher Hawkes
    Affiliations
    Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, 5 East 98th Street; Box 1138, New York, NY 10029-6574, United States
    Search for articles by this author
  • Fred Lublin
    Correspondence
    Corresponding author. Tel.: +1 212 241 6854.
    Affiliations
    Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, 5 East 98th Street; Box 1138, New York, NY 10029-6574, United States
    Search for articles by this author
      This our largest issue of MSARD, thanks to the outstanding and growing number of high quality submissions to this new journal. We have 4 reviews starting with a provocative analysis of the state of MS genetics by Co-Chief Editor, Chris Hawkes. It is our hope that his pointed opinions will generate lively discourse on the topic. This journal and others have had many papers on the relative roles of genetics, epigenetics and environmental factors in susceptibility to MS and we expect that there will be many more as these areas are developed and continue to converge. There is a review of CNS vasculitis in children by Twilt and Benseler. Galetta and Balcer review the insights coming from new tools for analyzing visual pathways in patients with MS. The last review by Kowalec and colleagues discusses the potential use of pharmacogenomics to assist identification of adverse drug reactions and interactions.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect